News | June 10, 2022
Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
Based on a post hoc analysis, fewer required respiratory interventions
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The drug will be manufactured at the group’s topical facility at Ahmedabad
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Subscribe To Our Newsletter & Stay Updated
